Many activities are underway to fully exploit AI’s potential within regulatory processes, both at the EU and international levels. The latest report by the European Medicines Agency discusses advances in policy and guideline development, new AI applications, and collaborations with industry and other regulators to identify emerging opportunities and develop a common approach.